News

Gene therapy has emerged as a groundbreaking approach for addressing a wide array of genetic disorders. With over 30 gene therapies approved by the FDA and more than 2000 in various stages of development globally, the potential for transformative treatments continues to expand. Recombinant Adeno-Associated Viral (AAV) vectors serve as…

Read more

Company to show production of multiple serotypes of recombinant adeno-associated viral (rAAV) vectors and rAAV production in suspension-adapted cell line AE1-BHK-SMorphology of adherent AE1-BHK (A) and suspension AE1-BHK-S (B) cells at 40X magnificationAgathos Biologics, a genetic medicine biotechnology company, will present data at the 27th Annual Meeting of the American…

Read more

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Read more

Agathos Biologics, a biotechnology company developing transformational science within a strong ethical and moral framework, today announced the company has been awarded $300,000 from the 2023 North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program.

Read more

Agathos Biologics will present data at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) on the Agathos BHK-[wt E1] and GH329 cell lines for producing recombinant adeno-associated virus (rAAV).

Read more

With a focus on high-content imaging and digital PCR, Agathos scientists use state-of-the-art technology to deliver unparalleled accuracy and reliability in nucleic acid quantification and cell analysis.

Read more

Voigt's responsibilities include managing laboratory operations and evaluating technology and market opportunities.

Read more

Agathos Biologics expands its laboratory and office space, bringing its total to 10,000 square feet of usable space.

Read more

Agathos Biologics, a biotechnology company developing transformational science within a strong ethical and moral framework, today announced the company has been awarded $900,000 from the North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program.

Read more

As we seek to build Agathos Biologics, it’s important to state our mission, values and strategy. We will look for opportunities to refine and further communicate in these areas, and one way to do this is to respond to relevant current events.

Read more